215 related articles for article (PubMed ID: 31150009)
1. Polypills for primary prevention of cardiovascular disease.
Chow CK; Meng Q
Nat Rev Cardiol; 2019 Oct; 16(10):602-611. PubMed ID: 31150009
[TBL] [Abstract][Full Text] [Related]
2. Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.
Webster R; Rodgers A
Curr Cardiol Rep; 2015 Dec; 17(12):121. PubMed ID: 26497041
[TBL] [Abstract][Full Text] [Related]
3. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
4. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
[TBL] [Abstract][Full Text] [Related]
5. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
6. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
7. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
Roy A; Naik N; Srinath Reddy K
Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
[TBL] [Abstract][Full Text] [Related]
8. Is a statin as part of a polypill the answer?
Robinson JG
Curr Atheroscler Rep; 2009 Jan; 11(1):15-22. PubMed ID: 19080723
[TBL] [Abstract][Full Text] [Related]
9. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
10. [The Polypill - A Practicable Approach?].
Thürmann PA; Kleinerüschkamp AG; Boehme P
Dtsch Med Wochenschr; 2019 Jun; 144(11):715-718. PubMed ID: 31163467
[TBL] [Abstract][Full Text] [Related]
11. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
12. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
[TBL] [Abstract][Full Text] [Related]
13. Polypills for the prevention of Cardiovascular diseases.
Kolte D; Aronow WS; Banach M
Expert Opin Investig Drugs; 2016 Nov; 25(11):1255-1264. PubMed ID: 27645895
[TBL] [Abstract][Full Text] [Related]
14. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
15. Preventing cardiovascular disease in New Zealand: making better use of statins but also tobacco control, changing the food supply and other strategies.
Wilson N; Jones AC; Nghiem N; Blakely T
N Z Med J; 2018 Oct; 131(1484):61-67. PubMed ID: 30359357
[TBL] [Abstract][Full Text] [Related]
16. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
17. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
; Yusuf S; Attaran A; Bosch J; Joseph P; Lonn E; McCready T; Mente A; Nieuwlaat R; Pais P; Rodgers A; Schwalm JD; Smith R; Teo K; Xavier D
Eur Heart J; 2014 Feb; 35(6):353-64. PubMed ID: 24288261
[TBL] [Abstract][Full Text] [Related]
18. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
19. Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study.
Salam A; Praveen D; Patel A; Tewari A; Webster R
Glob Heart; 2019 Sep; 14(3):303-310. PubMed ID: 31451238
[TBL] [Abstract][Full Text] [Related]
20. Multi-constituent cardiovascular pills (MCCP)--challenges and promises of population-based prophylactic drug therapy for prevention of heart attack.
Jamieson MJ; Naghavi M
Curr Pharm Des; 2007; 13(10):1069-76. PubMed ID: 17430169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]